RUNX1 methylation-Thyroid cancer.sav

<b>目的：</b> 在活检不确定的情况下，准确识别甲状腺结节的恶性肿瘤仍然是一个挑战。，甲状腺状癌 （PTC） 的异常 DNA 甲基化特征（良性甲状腺结节 （BTN） 相比 <b>方法：</b> 采用850K阵列和RNA测序对早期PTC和BTN组织样本进行基因组分析。鉴定出的基因在两项使用质谱法的独立病例对照研究中得到了验证。<b>结果：</b> 的低甲基化 PTC 中 RUNX1 （所有 OR ≥ 1.50）。RUNX1化取得了良好的准确性，在区分正在 早期PTC和BTN <b>结论</b><b>s</b><b>：</b> 我们揭示了 之间的 运行X1 与PTC表明RUNX1甲基化是伴随诊断甲状腺结节恶性结节的潜在生物标志物。<b>Purpose:</b> Accurate identification of malignant thyroid nodules remains a clinical challenge, especially when biopsy results are inconclusive. Compared with benign thyroid nodules (BTN), papillary thyroid carcinoma (PTC) exhibits aberrant DNA methylation profiles. <b>Methods:</b> Genomic analyses were performed on tissue samples from early-stage PTC and BTN using the 850K methylation array and RNA sequencing. Identified genes were validated in two independent mass spectrometry-based case-control studies. <b>Results:</b> RUNX1 was hypomethylated in PTC, with all odds ratios (ORs) ≥ 1.50. RUNX1 methylation achieved favorable diagnostic accuracy in distinguishing early-stage PTC from BTN. <b>Conclusions:</b> Our study revealed the association between RUNX1 and PTC, indicating that RUNX1 methylation serves as a potential biomarker for companion diagnosis of malignant thyroid nodules.